Composition:
Ferric Pyrophosphate, L-Lysine, Vitamin B12 & Vitamin C Drops
Ferric Pyrophosphate (Liposomal Iron) 12.5 mg, L-lysine 0.15 mg, Vitamin B12 0.5 mcg, Vitamin C 40 mg, Excipients q.s
Pediatrics: In children with IDA, liposomal iron has shown superior improvement in hemoglobin and, importantly, better patient compliance due to reduced side effects.
Composition:
Ferric Pyrophosphate, L-Lysine, Folic acid, Vitamin C & B12 Syrup
Elemental Iron (Ferric Pyrophosphate as Liposomal Iron) 29 mg, L-lysine 35 mg,
Folic Acid 500 mcg, Vitamin C 40 mg, Vitamin B12 0.75 mcg, Excipients q.s
Pregnancy: Studies indicate that liposomal iron significantly increases haemoglobin and ferritin levels in pregnant women, even with lower daily elemental iron doses (14mg or 29mg) compared to traditional iron salts.
Liposomal iron often containing ferric pyrophosphate are a "next-generation" oral iron therapy designed to overcome the limitations of conventional iron salts (like ferrous sulfate) by bypassing the high hepcidin-mediated blockade, making them highly effective in treating iron deficiency anemia (IDA) even during inflammation.
Hepcidin's Role: Hepcidin is a hormone produced by the liver that controls systemic iron balance.
The Blockade: When iron is high or when the body is under inflammation (e.g., chronic disease, infection), hepcidin levels rise. High hepcidin binds to ferroportin the only cellular iron exporter causing its degradation.
Result: Iron becomes trapped inside intestinal cells (enterocytes) and macrophages, unable to reach the bloodstream, causing low serum iron and "iron-restricted anemia".
Non-Conventional Absorption: Unlike traditional iron that requires ferroportin to exit the enterocyte, Increafer-LZ iron is encapsulated in a phospholipid bilayer vesicle. It is absorbed via endocytosis through M-cells in the intestine and through the lymphatic system, bypassing the traditional ferroportin-mediated pathway.
Direct Delivery: Due to this "Trojan Horse" mechanism, the iron is delivered directly to the liver without requiring the "gatekeeper" ferroportin, meaning it is not blocked by high hepcidin levels.
Superior Bioavailability: Liposomal iron (e.g., Increfer-LZ) is reportedly 2.7 to 3.5 times more bio available than ferrous sulphate.
Reduced Side Effects: Because the iron is encapsulated and does not interact directly with the gastrointestinal mucosa, it minimizes common GI distress such as nausea, constipation, and vomiting.
High Tolerance in Inflammation: Studies show that liposomal iron is a safe and effective alternative to intravenous (IV) iron for correcting anaemia in patients with Chronic Kidney Disease (CKD) or Refractory Anaemia (e.g., Myelodysplastic Syndrome - MDS).
No Food Interaction: Absorption of liposomal iron is not inhibited by dietary factors, allowing it to be taken with or without food.